Vision often worsens early in nonarteritic anterior ischemic optic neuropathy, and a past episode in the other eye predicts ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple sclerosis.

Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate privosegtor (formerly known as OCS-05) for the treatment of optic neuritis (ON). 1 ...

Millions of people are now using weight-loss drugs, but it seems there are side-effects that come with the slimmer waistlines ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Research unveiled more possible safety signals and benefits ...

Weight-loss injections - miracle solution for the millions unable to tackle excess weight by conventional means? Or sticking ...